A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia | MicrobiomeTrials← Back to trialsNCT07269210
A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-12-08Est. Completion: 2027-03
Enrollment target: 60 participants Locations- Onyx Clinical Research, Phoenix, Arizona, United States
- Synexus Clinical Research US, Inc./Orange Grove Family Practice, Tucson, Arizona, United States
- National Heart Institute, Beverly Hills, California, United States
- Ark Clinical Research, Long Beach, California, United States
- Catalina Research Institute, LLC, Montclair, California, United States
- Valley Clinical Trials, LLC dba Flourish Research, Northridge, California, United States
- CMR of Greater New Haven, LLC, Hamden, Connecticut, United States
- Northeast Research Institute - Downtown Office, Jacksonville, Florida, United States
- Novera Clinical Research, Miami, Florida, United States
- Inpatient Research Clinic, Miami Lakes, Florida, United States
- Clinical Site Partners, LLC dba Flourish Research, Winter Park, Florida, United States
- Great Lakes Clinical Trials - Ravenswood, Chicago, Illinois, United States
- Investigators Research Group, Brownsburg, Indiana, United States
- Saint Elizabeth Healthcare - Saint Elizabeth Covington Hospital, Covington, Kentucky, United States
- Flourish Research - Bowie, Bowie, Maryland, United States
Other microbiome trials you might be interested in
CardiovascularMetabolic DiseaseDyslipidemiasLipid DisorderHypertriglyceridemiaHeterozygous Familial Hypercholesterolemia (HeFH)Homozygous Familial Hypercholesterolemia (HoFH)Severe Hypertriglyceridemia (sHTG)Mixed HyperlipemiaHypercholesterolaemia
This is a single-arm, open-label, multicenter, ascending dose Phase 1 trial that will enroll participants 18 to 75 years…
Hialeah, United StatesEst. completion Jun 2027
University of Massachusetts Chan Medical School, Worcester, Massachusetts, United StatesAB Clinical Trials, Las Vegas, Nevada, United StatesClinical Research of Philadelphia, Pennington, New Jersey, United StatesWeill Cornell Medical College, New York, New York, United StatesIcahn School of Medicine at Mount Sinai, New York, New York, United StatesCardiovascular Specialists of Willowbrook, Houston, Texas, United StatesSouthern Endocrinology Associates, Mesquite, Texas, United StatesAmerican Research Corporation at Texas Liver Institute, San Antonio, Texas, United StatesEndeavor Clinical Trials, San Antonio, Texas, United StatesStroobants Cardiovascular Center, Lynchburg, Virginia, United StatesTPMG (Tidewater Physicians Multispecialty Group) Clinical Research, Newport News, Virginia, United StatesCarilion Clinic, Roanoke, Virginia, United StatesEastside Research Associates, Redmond, Washington, United StatesUW Medicine Diabetes Institute, Seattle, Washington, United StatesEcogene-21, Chicoutimi, CanadaC.I.C. Mauricie inc., Trois-Rivières, CanadaARC Biosystems, Vancouver, CanadaPeking University Third Hospital, Beijing, ChinaSichuan Provincial People's Hospital, Chengdu, ChinaGuangdong Provincial People's Hospital, Guangzhou, ChinaThe First Affiliated Hospital of Henan University of Science &Technology, Luoyang, ChinaZhongshan Hospital,Fudan University, Shanghai, ChinaThe Affiliated Hospital of Xuzhou Medical College, Xuzhou, ChinaThe Institute of Medical Science, Asahi Life Foundation, Chūōku, JapanTakai Internal Medicine Clinic, Kamakura-shi, JapanMedical Corporation Heishinkai OCROM Clinic, Suita-shi, JapanPhase 2
Recruiting
Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis
Phase II clinical trial evaluating the efficacy and safety of HRS-7249 and SHR-1918 in patients with severe hypertriglyc…
Nanjing, ChinaEst. completion Jun 2027